Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.

Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only ...

Friday, Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), announced the FDA approved Simlandi (adalimumab-ryvk) injection ...

Blue Shield of California is bypassing traditional pharmacy benefit managers to offer a Humira (adalimumab)-referenced biosimilar named Idacio to patients at the lowest list price currently ...